www.sativex.at

0: HTTP/1.1 301 Moved Permanently
Location: http://www.gwpharm.co.uk/sativex.asp
Location: http://www.gwpharm.co.uk/Sativex.aspx
Vary: Accept-Encoding
Content-Type: text/html; charset=iso-8859-1
Content-Type: text/html; charset=UTF-8
Content-Type: text/html; charset=utf-8
Server: NetNames
Server: Microsoft-IIS/7.5
Server: Microsoft-IIS/7.5
Date: Mon, 14 Dec 2015 10:18:42 GMT
Date: Mon, 14 Dec 2015 10:18:42 GMT
Date: Mon, 14 Dec 2015 10:18:42 GMT
Connection: close
Connection: close
Connection: close
1: HTTP/1.1 301 Moved Permanently
Content-Length: 160
Content-Length: 9630
2: HTTP/1.1 200 OK
Cache-Control: private
X-AspNet-Version: 2.0.50727

keywords: Sativex® is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain...Sativex® has now been launched in 15 countries (including the UK, Spain, Italy and Germany) and approved in a further 12.UK Information for Physicians and PatientsPatient InformationInformation regarding MS trials, general spasticity information and patient organisationsPrescriber InformationInformation for physicians on the availability of Sativex in different countriesSativex R&DA path to new treatments for indications other than spasticity, for example, cancer painPublicationsDetails of peer-review publications from completed clinical trials of Sativex.Partners GW has partnered with companies to market Sativex in countries around the world.Mechanism of Action Pharmacology of Sativex and how its principal active components act in the body.Please note that we cannot provide advice on the suitability of Sativex for individual patients.Patients wishing to know more about Sativex should discuss with their doctor the most suitable treatment for them.
description: Sativex® is a cannabinoid medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain...Sativex® has now been launched in 15 countries (including th...